Potential conflict of interest: Dr. Harrison advises and is on the speakers' bureau for Merck and Vertex. He consults for and advises CLDF.
Small steps toward a better treatment for chronic hepatitis C infection: mericitabine, pegylated interferon, and ribavirin in the PROPEL and JUMP-C trials
Article first published online: 28 JUN 2013
Copyright © 2013 by the American Association for the Study of Liver Diseases
Volume 58, Issue 2, pages 488–490, August 2013
How to Cite
Torres, D. M. and Harrison, S. A. (2013), Small steps toward a better treatment for chronic hepatitis C infection: mericitabine, pegylated interferon, and ribavirin in the PROPEL and JUMP-C trials. Hepatology, 58: 488–490. doi: 10.1002/hep.26438
The views expressed herein are those of the authors and do not reflect the official policy or position of the San Antonio Military Medical Center, the US Army Medical Department, the US Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the US Government.
- Issue published online: 29 JUL 2013
- Article first published online: 28 JUN 2013
- Accepted manuscript online: 4 APR 2013 05:04AM EST
- Manuscript Accepted: 1 APR 2013
- Manuscript Revised: 27 MAR 2013
- Manuscript Received: 11 FEB 2013
This article has been cited by:
- 1Current race in the development of DAAs (direct-acting antivirals) against HCV, Biochemical Pharmacology, 2014, 89, 4, 441,